Inst. Holders
17 funds
SYBX
SYNLOGIC, INC.
$1.11 ▼ -0.89%
Prev close $1.12High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on SYBX right now — valuation, ownership and activity at a glance.
Inst. Value
$655.2K
Inst. Activity
1 buys / 0 sells
Insider Activity
$0.00 buy / $0.00 sell
SEC Reports
3
Price chart 30d -9.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 5, 2026 earnings_calendar
Jul 29, 2026 SEC SYBX Q2 2026 Earnings Scheduled — 2026-08-05
Synlogic (SYBX) has entered into a definitive merger agreement with Caldera Therapeutics, a private biotech, via a rever
425, 8-K — Impact 7/10
Jul 27, 2026 Insider
New Enterprise Associates 14, L.P. bought 2,640,845 shares
Director
Jul 27, 2026 Insider
May 18, 2026 SEC New Enterprise Associates 14, L.P. disposed of 2,640,845 shares
Director
Nasdaq has finalized the delisting of Synlogic, Inc. (SYBX) common stock, effective May 28, 2026, following a withdrawal
25-NSE — Impact 7/10
Synlogic filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III items (director/officer info, executive
10-K/A — Impact 2/10
Dec 31, 2025 Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
85,627 shares ($95.9K)
Sep 30, 2025 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
39,510 shares ($65.9K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Mar 20, 2024 | HC Wainwright & Co. | UPGRADE | Neutral | 43% |
| Feb 9, 2024 | Chardan Capital | DOWNGRADE | Neutral | 49% |
| Feb 9, 2024 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Feb 9, 2024 | HC Wainwright & Co. | DOWNGRADE | Sell | 43% |
| Dec 11, 2023 | Alliance Global Partners | INITIATE | Buy | 42% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% |
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 1 neutral · avg impact 5.3/10.
BEARISH425, 8-K7/10
Synlogic (SYBX) has entered into a definitive merger agreement with Caldera Therapeutics, a private
Jul 29, 2026
BEARISH25-NSE7/10
Nasdaq has finalized the delisting of Synlogic, Inc. (SYBX) common stock, effective May 28, 2026, fo
May 18, 2026
NEUTRAL10-K/A2/10
Synlogic filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III items (director/offi
Apr 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 5, 2026
earnings_calendar
SYBX Q2 2026 Earnings Scheduled — 2026-08-05
May 6, 2026
earnings_calendar
SYBX Q1 2026 Earnings Scheduled — 2026-05-06
Mar 4, 2026
earnings_calendar
SYBX Q4 2025 Earnings After Market Close — 2026-03-04
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own SYBX (from quarterly 13F filings) and who is adding or trimming.
17 institutional holders with $655.2K total value (585,005 shares) as of 2025-Q4. Top holders: VANGUARD, CITADEL, RENAISSANCE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top holders — 2025-Q4
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD GROUP INC | 201,060 | $225.2K | 34.4% | — |
| CITADEL ADVISORS LLC | 141,608 | $158.6K | 24.2% | TRIM -43.0% |
| RENAISSANCE TECHNOLOGIES LLC | 85,627 | $95.9K | 14.6% | DOUBLED +116.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 71,645 | $80.2K | 12.2% | — |
| BlackRock, Inc. | 19,757 | $22.1K | 3.4% | — |
| NORTHERN TRUST CORP | 19,469 | $21.8K | 3.3% | — |
| JANE STREET GROUP, LLC | 14,998 | $16.8K | 2.6% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11,623 | $13.0K | 2.0% | — |
| STATE STREET CORP | 10,176 | $11.4K | 1.7% | — |
| FMR LLC | 5,323 | $6.0K | 0.9% | NEAR_EXIT -96.8% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 39,510 | 85,627 | +116.7% | $95.9K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 23,810 | 39,510 | +65.9% | $65.9K |
| FMR LLC | NEAR_EXIT | 166,001 | 5,323 | -96.8% | $9.0K |
| JPMORGAN CHASE & CO | NEAR_EXIT | 7 | 1 | -85.7% | $1.00 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 71,928 | 22,310 | -69.0% | $31.2K |
| FMR LLC | TRIM | 230,209 | 166,724 | -27.6% | $248.4K |
| CITADEL ADVISORS LLC | TRIM | 28,850 | 16,449 | -43.0% | $24.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 2 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | New Enterprise Associates 14, L.P. | Director | BUY | 2,640,845 | — | — |
| Jul 27, 2026 | New Enterprise Associates 14, L.P. | Director | H | 2,640,845 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SYBX.
Shares short
2,947
Settlement Sep 15, 2026
Change vs prior
-17.3%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
All SYBX filing & press-release reports (3)
- 425, 8-K reportJul 29, 2026
- 25-NSE reportMay 18, 2026
- 10-K/A reportApr 30, 2026